依洛尤单抗对FOURIER试验中所有血管区域急性动脉事件的影响
FOURIER试验纳入27 564例接受他汀治疗的稳定性动脉粥样硬化性心血管疾病(ASCVD)患者,随机给予依洛尤单抗或安慰剂。依洛尤单抗使首次急性动脉事件减少19%(HR 0.81,95%CI 0.74-0.88,P<0.001),冠脉、脑血管和外周血管事件均显著下降,总事件减少24%。
要点
- 依洛尤单抗使首次急性动脉事件减少19%,冠脉、脑血管及外周血管事件均显著降低。
- 总事件(首次加复发)减少24%,且效应随时间增强,第一年减少16%,之后减少24%。
- 急性动脉事件中74%为冠脉、22%为脑血管、4%为外周血管。
核心结论
- 在他汀治疗基础上加用PCSK9抑制剂依洛尤单抗可减少所有血管区域的急性动脉事件,且随时间显示稳健效应,提示强化降脂治疗对这些急性且临床有意义的事件具有泛血管影响。
研究设计与样本
- FOURIER试验为随机对照试验,纳入27 564例接受他汀治疗的稳定性ASCVD患者,随机分配至依洛尤单抗或安慰剂组。
主要发现
- 2210例首次急性动脉事件中,74%为冠脉、22%为脑血管、4%为外周血管。
- 依洛尤单抗减少首次急性动脉事件19%(HR 0.81,95%CI 0.74-0.88,P<0.001)。
- 急性冠脉事件减少(HR 0.83,95%CI 0.75-0.91),脑血管事件减少(HR 0.77,95%CI 0.65-0.92),外周血管事件减少(HR 0.58,95%CI 0.38-0.88)。
- 总事件(首次加复发)共3437例,依洛尤单抗减少24%(发生率比0.76,95%CI 0.69-0.85)。
- 第一年急性动脉事件减少16%(HR 0.84,95%CI 0.75-0.95),之后减少24%(HR 0.76,95%CI 0.67-0.85)。
临床怎么用
- 对于接受他汀治疗的稳定性ASCVD患者,加用依洛尤单抗可全面降低冠脉、脑血管和外周血管的急性事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We assessed the impact of the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab on acute arterial events across all vascular territories, including coronary, cerebrovascular, and peripheral vascular beds, in patients with established atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: In the FOURIER trial, 27 564 patients with stable ASCVD on statin therapy were randomly assigned to evolocumab or placebo. Acute arterial events were a composite of acute coronary (coronary heart disease death, myocardial infarction, or urgent coronary revascularization), cerebrovascular (ischaemic stroke, transient ischaemic attack, or urgent cerebral revascularization), or peripheral vascular (acute limb ischaemia, major amputation, or urgent peripheral revascularization) events. Of the 2210 first acute arterial events, 74% were coronary, 22% were cerebrovascular, and 4% were peripheral vascular. Evolocumab reduced first acute arterial events by 19% (hazard ratio [HR] 0.81 [95% confidence interval 0.74-0.88]; P < 0.001), with significant individual reductions in acute coronary (HR 0.83 [0.75-0.91]), cerebrovascular (HR 0.77 [0.65-0.92]), and peripheral vascular (HR 0.58 [0.38-0.88]) events. There were 3437 total events (first plus recurrent), with evolocumab reducing total events by 24% (incidence rate ratio 0.76 [0.69-0.85]). The magnitude of reduction in acute arterial events with evolocumab numerically increased over time, with a 16% reduction (HR 0.84 [0.75-0.95]) in the first year followed by a 24% reduction (HR 0.76 [0.67-0.85]) thereafter. CONCLUSION: The addition of the PCSK9 inhibitor evolocumab to statin therapy reduced acute arterial events across all vascular territories with a robust effect over time, indicating a pan-vascular impact of aggressive lipid-lowering therapy on these acute and clinically meaningful events. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.
引用
- Oyama K, Giugliano RP, Tang M, et al. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J. 2021. PMID: 34537830. doi:10.1093/eurheartj/ehab604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。